论文部分内容阅读
Somatix公司计划在今年年底之前开展其获准的第一项基因治疗的尝试,以用于肾癌的治疗。这一尝试将在Johns Hopkins大学进行,包括取出病人的癌细胞,利用该公司适当的载体将GM-CSF基因插入细胞,再把改造后的细胞回输病人,使其发挥“疫苗”的作用,对抗癌细胞。这一探讨在小鼠的肿瘤模型上非常见效,但是否能成功地适用于人体还不能肯定。如果这一方案获得成功的话,该公司计划于1993年下半年或1994年上半年开始临床Ⅱ、Ⅲ期试验。这一基因治疗的策略还可以将其他细胞因子如IL-2、IL-4等应用于其他种
Somatix plans to launch its first approved gene therapy trial before the end of this year for the treatment of kidney cancer. This attempt will be carried out at the University of Johns Hopkins, including taking out cancer cells from the patient, inserting the GM-CSF gene into cells using the company’s appropriate vectors, and transferring the transformed cells back to the patient so that it can function as a “vaccine.” Against cancer cells. This study is very effective in the tumor model of mice, but whether it can successfully apply to the human body is not yet certain. If this plan is successful, the company plans to begin Phase II and Phase III trials in the second half of 1993 or the first half of 1994. This gene therapy strategy can also apply other cytokines such as IL-2 and IL-4 to other species.